NASDAQ:JNCE Jounce Therapeutics (JNCE) Stock Price, News & Analysis → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Free JNCE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.88▼$1.9350-Day Range$1.84▼$1.9452-Week Range$0.58▼$5.87Volume11.60 million shsAverage Volume2.46 million shsMarket Capitalization$98.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Jounce Therapeutics alerts: Email Address Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Jounce Therapeutics Stock (NASDAQ:JNCE)Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.Read More Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry JNCE Stock News HeadlinesNovember 27, 2023 | bizjournals.comSan Diego VC, OrbiMed make competing buyout offers for struggling TheseusSeptember 19, 2023 | tmcnet.comJounce Media Designates Yahoo Backstage as the Open Web's Largest MFA-Free Supply SourceApril 25, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.September 18, 2023 | finance.yahoo.comKargo Is Industry’s Only Scaled 100% Premium SSP According To Jounce MediaSeptember 5, 2023 | tmcnet.comMediavine Represents the Largest Percentage of DEI-owned Websites, Per Data from Jounce MediaMay 5, 2023 | benzinga.comBoard Member at Jounce Therapeutics Exercises Options Worth $324KMay 4, 2023 | benzinga.comBoard Member at Jounce Therapeutics Exercises Options Worth $172KMay 4, 2023 | benzinga.comJounce Therapeutics Director Acquires 51,400 Shares After Exercising Company Stock OptionsApril 25, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.May 4, 2023 | benzinga.comJounce Therapeutics Board Member Acquires 1,883,269 Shares After Exercising Company Stock OptionsMay 3, 2023 | finance.yahoo.comJounce Therapeutics Announces Closing of Tender OfferApril 29, 2023 | seekingalpha.comJNCE Jounce Therapeutics, Inc.April 17, 2023 | finance.yahoo.comThe past five years for Jounce Therapeutics (NASDAQ:JNCE) investors has not been profitableMarch 29, 2023 | benzinga.comWhat is Wall Street's Target Price for Jounce Therapeutics Inc (JNCE) Stock Monday?March 27, 2023 | msn.comBuyout Offer Sends Jounce Jumping 20%March 27, 2023 | marketwatch.comJounce Therapeutics Shares Rally on Buyout Deal >JNCEMarch 27, 2023 | marketwatch.comJounce Therapeutics Agrees to Buyout, Drops Redx Deal >JNCEMarch 27, 2023 | finance.yahoo.comJounce dumps Redx Pharma for acquisition by Concentra; to cut 84% of jobsMarch 23, 2023 | benzinga.comMoore Kuehn Encourages JNCE, USX, INDT, and BHWB Investors to Contact Law FirmMarch 17, 2023 | 247wallst.comTang Capital Partners Now Owns 10.2% of Jounce TherapeuticsMarch 16, 2023 | finance.yahoo.comJounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian CancerMarch 16, 2023 | finance.yahoo.comJounce (JNCE) Up 41% on Buyout Offer From Concentra BiosciencesMarch 15, 2023 | benzinga.com10% Owner of Jounce Therapeutics Makes $85K BuyMarch 15, 2023 | finance.yahoo.comWhy Jounce Therapeutics Stock Is Moving Higher Today?March 15, 2023 | markets.businessinsider.comConcentra Biosciences Proposes To Acquire Jounce Therapeutics - Quick FactsMarch 15, 2023 | msn.comTang Capital Partners Now Owns 10.20% of Jounce Therapeutics (JNCE)March 15, 2023 | marketwatch.comJounce Therapeutics Jumps Premarket on Buyout Bid >JNCESee More Headlines Receive JNCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:JNCE CUSIPN/A CIK1640455 Webwww.jouncetx.com Phone(857) 259-3840FaxN/AEmployees137Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,920,000.00 Net MarginsN/A Pretax Margin-61.93% Return on Equity-30.90% Return on Assets-26.31% Debt Debt-to-Equity RatioN/A Current Ratio8.37 Quick Ratio8.37 Sales & Book Value Annual Sales$82 million Price / Sales1.21 Cash FlowN/A Price / Cash FlowN/A Book Value$3.54 per share Price / Book0.53Miscellaneous Outstanding Shares52,630,000Free Float48,993,000Market Cap$98.94 million OptionableOptionable Beta0.75 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesKimberlee Cobleigh DrapkinPresident, Chief Financial Officer & TreasurerEric LaubHead-Investor & Media RelationsTed HardingSenior Vice President-Human ResourcesJacquelyn Fahey SandellSecretary & Chief Legal OfficerAllison NanceVP-Regulatory Affairs & Quality AssuranceKey CompetitorsVigil NeuroscienceNASDAQ:VIGLSangamo TherapeuticsNASDAQ:SGMObluebird bioNASDAQ:BLUEOutlook TherapeuticsNASDAQ:OTLKAlloVirNASDAQ:ALVRView All Competitors JNCE Stock Analysis - Frequently Asked Questions How were Jounce Therapeutics' earnings last quarter? Jounce Therapeutics, Inc. (NASDAQ:JNCE) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.15. During the same period last year, the firm posted ($0.73) EPS. What is Richard Murray Ph.D's approval rating as Jounce Therapeutics' CEO? 45 employees have rated Jounce Therapeutics Chief Executive Officer Richard Murray Ph.D on Glassdoor.com. Richard Murray Ph.D has an approval rating of 97% among the company's employees. This puts Richard Murray Ph.D in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Jounce Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Exelixis (EXEL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), CRISPR Therapeutics (CRSP), Novavax (NVAX), Mylan (MYL), Progenics Pharmaceuticals (PGNX), Adaptimmune Therapeutics (ADAP), Incyte (INCY) and Nektar Therapeutics (NKTR). When did Jounce Therapeutics IPO? Jounce Therapeutics (JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers. This page (NASDAQ:JNCE) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceGreat Crypto BullWeiss RatingsMan Who Predicted 2008: “This Will be Worse.”Altimetry"The Biggest Drug Ever" Is ComingBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jounce Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
